Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease. We show 37 historical shares outstanding datapoints in our ATRA shares outstanding history coverage, used to compute ATRA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ATRA market cap history over the course of time is important for investors
interested in comparing ATRA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ATRA versus a peer is one thing; comparing
ATRA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ATRA can fluctuate over the course of history.
With this page we aim to empower investors researching ATRA by allowing them to research the ATRA market cap history. |
Free ATRA Email Alerts:
Video: The Importance of Market Cap
